BioCryst Pharmaceuticals announced FDA approval of ORLADEYO 150 mg oral pellets for prophylactic treatment of hereditary angioedema (HAE) in adults and adolescents aged 12 and older. This pellet form offers an alternative to capsules, aiding patients who have difficulty swallowing or prefer not to take capsules. ORLADEYO is the first oral prophylactic therapy approved for HAE patients aged 2 and above, with proven efficacy in reducing attack rates by over 90%. The approval expands treatment options, supporting personalized care for HAE patients.
BioCryst's FDA approval of ORLADEYO 150 mg oral pellets offers new treatment options for hereditary angioedema. For readers following the health sector, here is Pluang's market snapshot as of Oct 21, 2026 18:11 WIB: out of 150 priced US health stocks, 71 rose and 67 fell. Notable movers include ZBH at USD 93.60 with 100% sell orders, SANA at USD 2.41 with 100% buy orders, and TXG at USD 70.00 with 92% sell orders.
The Human Feedback Foundation, supported by RBC, has launched the Agentic AI Design Exchange, a national program aimed at helping Canadian nonprofits design, build, and deploy AI agents responsibly. Funded through RBC's Stronger Nonprofits Program, t...
Satellos Bioscience Inc., a clinical-stage company focused on treatments for degenerative muscle diseases, announced its management will participate in two investor conferences in November: the Guggenheim Healthcare Innovation Conference on Nov 9 in ...
YYForce Inc. has purchased 20 wearable data collection systems to gather real task data from hotel room service at Novotel Singapore. This project aims to record and analyze experienced staff performing tasks like bed-making, towel folding, and clean...
The global digital health and remote patient monitoring market is projected to grow from $26.8 billion in 2025 to $80.8 billion by 2031, at a compound annual growth rate of 20.2%. This growth is driven by increasing demand for chronic disease managem...
The global private credit and alternative lending market, valued at $2.31 trillion in 2026, is expected to grow at a 7.8% CAGR to reach $3.36 trillion by 2031. Recent liquidity pressures in 2025, triggered by bankruptcies and AI sector concerns, caus...
